Research programme: tryptase inhibitors - Molecumetics/Ashai
Latest Information Update: 05 Feb 2007
Price :
$50 *
At a glance
- Originator Molecumetics
- Class Small molecules
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued CNS disorders; Inflammation; Metabolic disorders; Vascular disorders
Most Recent Events
- 08 Sep 1999 This programme is available for licensing in Europe and North America (http://www.molecumetics.com)
- 08 Sep 1999 Preclinical development for CNS disorders in USA (Unknown route)
- 08 Sep 1999 Preclinical development for Inflammation in USA (Unknown route)